Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19260559 | 0.92 | KDM4E (0.45) | CACNA2D1KDM4EALDH1A1USP2ALOX15 | |
| SCHEMBL19260524 | 0.89 | EGFR (0.50) | KDM4EEHMT2EGFRPOLBKMT2A | |
| SCHEMBL20734756 | 0.85 | EGFR (0.50) | CACNA2D1KDM4EALDH1A1USP2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL19260557 | 0.81 | EGFR (0.44) | KDM4EMAPK1EHMT2EGFRPOLB | |
| SCHEMBL19260688 | 0.79 | EHMT2 (0.56) | EHMT2 | |
| SCHEMBL20720605 | 0.78 | SPIN1 (0.56) | EHMT2 | |
| Trifluoroacetic Acid SCHEMBL19260723 | 0.77 | EGFR (0.46) | KDM4EALDH1A1USP2ALOX15MAPK1 | |
| SCHEMBL19260599 | 0.77 | EHMT2 (0.47) | MAPK1EHMT2EGFR | |
| SCHEMBL19260538 | 0.77 | MAP2K1 (0.61) | KDM4EMAPK1EGFRPOLBGAA | |
| SCHEMBL19260533 | 0.76 | MAP2K1 (0.46) | MAPK1EHMT2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | claimed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | claimed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | CACNA2D1 1539/4885KDM4E 42/4885ALDH1A1 1471/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CACNA2D1 771/4885KDM4E 52/4885ALDH1A1 1093/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CACNA2D1 1539/4885KDM4E 42/4885ALDH1A1 1471/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | CACNA2D1 771/4885KDM4E 52/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.